Study Design in Dementia Drug Trials
نویسندگان
چکیده
منابع مشابه
Global assessment measures for assessing efficacy in dementia drug trials.
The use of judgment-based global measures of clinical treatment effects has a long history in the regulatory approval of drugs for the treatment of dementia. This paper reviews current use of these measures, noting several practical difficulties with their implementation. Importantly, global measures have usually yielded general estimates of drug effects similar to psychometric test batteries, ...
متن کاملClinical Trials Study Design
Observational Studies: Observational studies provide a mechanism for clarifying the epidemiology and risk factors/exposures that place populations at risk for disease. Observational studies assist in identifying clinical outcomes that might aid in predicting future disease. This type of study allows researchers to draw conclusions about responses to variables; they allow for associations but no...
متن کاملDesign of clinical antiepileptic drug trials
It may fairly be claimed that up to the last decade no antiepileptic drug (AED) had undergone rigorous testing. The development programmes of the new AEDs registered in recent years have necessarily been innovative, and methods of AED testing are still undergoing rapid evolutionary change. Clinical evaluation of AEDs is both difficult and complex, due mainly to two factors: (1) intermittence of...
متن کاملOccurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study
INTRODUCTION Responsible conduct of research implies that results of clinical trials should be completely and adequately reported. This article describes the design of a cohort study that aims to investigate the occurrence and the determinants of selective reporting in an inception cohort of all clinical drug trials that were reviewed by the Dutch Institutional Review Boards (IRBs) in 2007. It ...
متن کاملDesign issues in pivotal drug trials for drug sensitive tuberculosis (TB).
The urgent need for new anti-tuberculosis drugs raises the question of the design, conduct and analysis of the trials that will be required for licensing purposes. Current standard regimens are highly effective under controlled trial conditions with relapse rates of 5% or less. It is very unlikely better results can be achieved with new drugs, a clinically more relevant goal would be a regimen ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
سال: 2007
ISSN: 0317-1671,2057-0155
DOI: 10.1017/s0317167100005503